Skip Navigation


Hum. Reprod. Advance Access originally published online on January 11, 2007
Human Reproduction 2007 22(4):1017-1020; doi:10.1093/humrep/del497
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
22/4/1017    most recent
del497v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Seifer, D. B.
Right arrow Articles by Cuckle, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seifer, D. B.
Right arrow Articles by Cuckle, H. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Serum müllerian-inhibiting substance in Down's syndrome pregnancies

David B. Seifer1, David T. MacLaughlin2 and Howard S. Cuckle3,4

1 Maimonides Medical Center, Brooklyn, New York 2 Massachusetts General Hospital, Harvard Medical School, Boston, USA 3 University of Leeds Medical School, Leeds, UK

4 To whom correspondence should be addressed at: Leeds Screening Centre, Gemini Park, Sheepscar Way, Leeds LS7 3JB, UK. Tel.: +44 113 284 9233; Fax: +44 113 262 1658; E-mail: h.s.cuckle{at}leeds.ac.uk

BACKGROUND: To examine whether maternal serum levels of müllerian-inhibiting substance (MIS) differ in Down's syndrome and unaffected pregnancies.

METHODS: Case–control study was conducted using stored serum from an antenatal screening programme. Sera from 25 Down's syndrome pregnancies were retrieved from –20°C storage together with 125 unaffected controls individually matched for maternal age, weeks of gestation and duration of storage. Results were expressed in multiples of the gestation-specific median value (MoM) in controls.

RESULTS: The median value in Down's syndrome pregnancies was 0.83 MoM (P = 0.77, two-tail Wilcoxon rank sum test). Among unaffected pregnancies, there was a statistically significant correlation between MIS and pregnancy-associated plasma protein-A (P < 0.05). MIS levels were elevated in pregnancies where assisted reproduction techniques had been used.

CONCLUSION: There is no evidence for a substantial reduction in maternal serum MIS levels in Down's syndrome pregnancies. This study provides useful information regarding serum MIS levels in pregnancy.

Key words: antenatal screening/Down's syndrome/marker/MIS/ovarian reserve

Submitted on July 24, 2006; resubmitted on October 18, 2006; resubmitted on November 30, 2006; accepted on December 5, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
M.L. Haadsma, T.M. Mooij, H. Groen, C.W. Burger, C.B. Lambalk, F.J.M. Broekmans, F.E. van Leeuwen, K. Bouman, A. Hoek, and on behalf of the OMEGA Project Group
A reduced size of the ovarian follicle pool is associated with an increased risk of a trisomic pregnancy in IVF-treated women
Hum. Reprod., November 17, 2009; (2009) dep404v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.